Who is sponsoring RP_MPR?

RP_MPR is sponsored by Fondazione EMN Italy Onlus.

What condition does RP_MPR study?

RP_MPR studies Multiple Myeloma.

What drugs are being tested in RP_MPR?

Interventions: RP followed by MPR.

Last reviewed 2023-06-28 · How we verify

A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients (RP_MPR)

NCT01160107 Phase 2 COMPLETED

This study will determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is safe and induce a significant rate of PR (and CR) in newly diagnosed elderly MM patients.

Details

Lead sponsor	Fondazione EMN Italy Onlus
Phase	Phase 2
Status	COMPLETED
Enrolment	46
Start date	2008-07
Completion	2022-12-22

Conditions

Multiple Myeloma

Interventions

RP followed by MPR

Primary outcomes

RP as induction followed by MPR as consolidation treatment is safe and induce a significant rate of PR (and CR) — Approximately 24 months
Determine whether the association of RP as induction followed by MPR as consolidation treatment is safe and induce a significant rate of PR (and CR) in elderly patients with newly diagnosed multiple myeloma.